{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:49:45Z","timestamp":1791928185214,"version":"4.3.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.3129\/i08-104","type":"journal-article","created":{"date-parts":[[2008,12,10]],"date-time":"2008-12-10T14:11:17Z","timestamp":1228918277000},"page":"576-580","source":"Crossref","is-referenced-by-count":15,"title":["Intravitreal bevacizumab for the treatment of choroidal neovascularization associated with pathological myopia"],"prefix":"10.1016","volume":"43","author":[{"given":"Marc-Andr\u00e9","family":"Rh\u00e9aume","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika\u00ebl","family":"Sebag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3129\/i08-104_bib1","series-title":"Retina","first-page":"1115","article-title":"Choroidal neovascular membrane in degenerative myopia","author":"Soubrane","year":"2006"},{"key":"10.3129\/i08-104_bib2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/112067219700700401","article-title":"Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment","volume":"7","author":"Secretan","year":"1997","journal-title":"Eur J Ophthalmol"},{"key":"10.3129\/i08-104_bib3","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0161-6420(01)00544-9","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial \u2014 VIP report no 1","volume":"108","year":"2001","journal-title":"Ophthalmology"},{"key":"10.3129\/i08-104_bib4","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0161-6420(02)01998-X","article-title":"Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial \u2014 VIP report no 3","volume":"110","year":"2003","journal-title":"Ophthalmology"},{"key":"10.3129\/i08-104_bib5","first-page":"1508","article-title":"Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration","volume":"113","author":"Chakravarthy","year":"2006","journal-title":"Ophthalmology"},{"key":"10.3129\/i08-104_bib6","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ophtha.2006.01.027","article-title":"Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration","volume":"113","author":"Rosenfeld","year":"2006","journal-title":"Ophthalmology"},{"key":"10.3129\/i08-104_bib7","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.3129\/i08-104_bib8","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"10.3129\/i08-104_bib9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/01.iae.0000238561.99283.0e","article-title":"Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration","volume":"26","author":"Spaide","year":"2006","journal-title":"Retina"},{"key":"10.3129\/i08-104_bib10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/bjo.2006.096776","article-title":"Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularization secondary to pathological myopia","volume":"91","author":"Yamamoto","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.3129\/i08-104_bib11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/bjo.2006.099887","article-title":"Intravitreal injection of bevacizumab for choroidal neovascularization associated with pathological myopia","volume":"91","author":"Sakaguchi","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.3129\/i08-104_bib12","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/01.iae.0000225766.75009.3a","article-title":"Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration","volume":"26","author":"Rich","year":"2006","journal-title":"Retina"},{"key":"10.3129\/i08-104_bib13","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3129\/i08-104_bib14","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3129\/i08-104_bib15","first-page":"510","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study","volume":"143","author":"Chen","year":"2007","journal-title":"Ophthalmology"},{"key":"10.3129\/i08-104_bib16","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/bjo.2006.099598","article-title":"The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide","volume":"90","author":"Fung","year":"2006","journal-title":"Br J Ophthalmol"},{"issue":"March","key":"10.3129\/i08-104_bib17","article-title":"Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia","author":"Mandal","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.3129\/i08-104_bib18","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/j.1600-0420.2006.00762.x","article-title":"Choroidal neovascularization treated with intravitreal injection of bevacizumab (Avastin) in angioid streaks","volume":"84","author":"Teixeira","year":"2006","journal-title":"Acta Ophthalmol Scand"},{"key":"10.3129\/i08-104_bib19","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10792-007-9036-y","article-title":"Rapid regression of extensive retinovitreal neovascularization secondary to branch retinal vein occlusion after a single intravitreal injection of bevacizumab","volume":"26","author":"Ahmadieh","year":"2005","journal-title":"Int Ophthalmol"},{"key":"10.3129\/i08-104_bib20","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.ajo.2006.06.066","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma","volume":"142","author":"Iliev","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.3129\/i08-104_bib21","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/bjo.2005.066431","article-title":"Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia","volume":"89","author":"Nguyen","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"10.3129\/i08-104_bib22","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","article-title":"Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study","volume":"112","author":"Michels","year":"2005","journal-title":"Ophthalmology"},{"key":"10.3129\/i08-104_bib23","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00006982-200603000-00001","article-title":"Testing intravitreal toxicity of bevacizumab (Avastin)","volume":"26","author":"Manzano","year":"2006","journal-title":"Retina"},{"key":"10.3129\/i08-104_bib24","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/00006982-200603000-00002","article-title":"Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin)","volume":"26","author":"Shahar","year":"2006","journal-title":"Retina"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418208800853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418208800853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T11:04:25Z","timestamp":1632740665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418208800853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S0008418208800853"],"URL":"https:\/\/doi.org\/10.3129\/i08-104","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}